The World Desk · slice 04
Health & Bio Desk
Regulatory decisions, clinical trials, and the oncology literature. This desk keeps the health slice of our record, from FDA actions to published research. Each finding shows how many separate publishers carried it.
$1.6T: annual sales of the global pharmaceutical market — industry estimates. On this desk’s wire right now: $19M in federal award records.
What this desk is
Regulatory decisions, clinical-trial readouts, drug and diagnostic approvals, and the oncology research frontier.
Not on this desk: Drug-enforcement and narcotics policing, dropped by name, and consumer wellness coverage that carries no clinical or regulatory finding.
- What is on the page now: 29 items from 21 sources, the earliest dated 2026-09-09. Drawn from 809 fresh items across 333 sources on this beat.
- How often it changes: rebuilt every snapshot; as of 2026-10-16.
- Daily brief: none yet. This desk has no daily brief; the page itself is the desk, rebuilt every snapshot.
- How a tier is earned: A tier is earned by independent origins, not by volume: each newsroom that reported an event on its own counts once, and every syndicated copy of a single wire counts once in total.
Contracts & awards
Award and solicitation records from SAM.gov and USAspending.
- LENCO INDUSTRIES, INC. — $2.2M — Drug Enforcement Administration: Department of Justice
- TEXTRON AVIATION INC — $16.8M — Drug Enforcement Administration: Department of Justice
- Medical Support Services for CBP (including medical exams, fitness for duty, drug testing, and related services): MISSION SUPPORT CONTRACTING DIVISION · Award Notice
- Q--Occupational Therapy for Lake Valley Navajo School: INDIAN EDUCATION ACQUISITION OFFICE · Award Notice
- Electro-Therapeutic Modalities for Pain Management (ETMPM) - Transcutaneous Electrical Nerve Stimulation (TENS) Procurement Program: COMMODITIES & SERVICES ACQUISITION SERVICE (36C791) · closes 2026-10-19
Also tracked on this desk
Subjects whose coverage concentrates in this desk’s domains. Each count is the number of stories in our archive.
On the desk wire
Names native to this desk moving across our whole record right now. Open one for momentum, coverage, and the read.
Our read
What more than one publisher carried on this desk between 2026-10-09 and 2026-10-15, as of 2026-10-15. The count is publishers: a wire story picked up by fifteen outlets counts once.
Carried by more than one publisher Measured
No event on this desk had more than one publisher in the window.
Changed since the last snapshot Measured
- Nothing entered or left this desk’s corroborated list since the last snapshot.
Not yet read on this desk: single-publisher events; contradictions. Not yet read is not the same as none.
This counts how many separate publishers carried an event. It does not show whether the event is true. Many outlets repeating one official statement still rest on one source. The whole week’s corroborated record.
In the coverage
What this desk’s sources reported most recently, newest first: the links behind the read above. Distilled from 809 fresh items across 333 sources on this desk’s beat; the full record feeds every desk, and these are the top reads.
- Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
- FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
- Guinea-Bissau denies it has approved controversial vaccine trial in newborns
- BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
- Efficacy and Safety of Fruquintinib Plus TAS-102 in Patients With Previously Treated Metastatic Colorectal Cancer: Results From a Single-Arm, Multi-Center, Phase II Study
- Multimodal Machine Learning-Based Clinical and Genomic Prognostic Factors for Progression-Free Survival in Metastatic Breast Cancer Using Phase III MONALEESA Trials
- PVX-001: open-source Covid-19 vaccine starts Phase 1 trial
- Fierce Pharma Asia—Novartis’ $7.8B mRNA deal; Shionogi’s $2B buy; ArriVent’s phase 3 flop
- Zoetis IB poultry vaccine receives expanded label approval
- Postoperative chemotherapy reintroduction in good responders after colorectal liver metastases resection: A French randomized phase III trial - IRIMAD.
- FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer
- BMS fills out Zenbexus picture with post-approval PFS victory in multiple myeloma
- REVERCE II: A Phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer.
- Lanreotide for Advanced Pheochromocytoma and Paraganglioma: Results of a Multicenter Phase II Trial
- A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer.
- FDA Approves First Heart Valve Designed to Grow with Children
- Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial
- Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial.
- Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial.
- Corrigendum to “Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 347
- EGFR targeting with afatinib and cetuximab versus cetuximab alone in chemorefractory wild-type RAS metastatic colorectal cancer. A randomized phase II study with circulat
- Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer
- Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Tria
Ask the record
No subject on this desk was carried by more than one publisher in the current window, so there is no question to suggest. Ask a question of the record about any subject.
Follow the Health & Bio Desk
This desk has no daily brief yet. The page is rebuilt with every snapshot and shows what more than one publisher carried and what changed since the last one. Leave your address and we will write once, when the Health & Bio Desk brief starts. Nothing else is sent.
Informational only, not investment advice. Market-size figures are editorial estimates with sources as noted; contract and award lines are drawn from public federal records via our tracked pipelines.